ZZ Biotech
ZZ Biotech is a privately held, Houston-based clinical-stage biotech developing 3K3A-APC, an engineered variant of human activated protein C, and has licensed its dermatology program to Dermatherix for wound-therapy development.
- Company typePrivate
- Founded2006
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ZZ Biotech does
ZZ Biotech, LLC is a privately held, clinical-stage biotechnology company founded in 2006 and headquartered at 4265 San Felipe St., Suite 1100, Houston, Texas. It was originally positioned around biologic treatments for ischemic stroke and currently operates with a 1–10 employee footprint under CEO Kent Pryor, with Berislav V. Zlokovic listed as co-founder.
The company's core technology is 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease that has been optimized for human therapeutic use. Rather than commercialize directly, ZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., positioning the asset in wound-therapy and dermatological applications while ZZ Biotech retains the underlying development activities.
From a business-model perspective, ZZ Biotech is pre-revenue from product sales and is pursuing a licensing/royalty monetization path via the Dermatherix relationship. Its funding history is limited and dated: a $1.0M round in March 2014 led by the National Institutes of Health with Broadview Ventures, and a $6.925M round in 2015 with undisclosed investors. The company also acquired Bioatrix in January 2016 for an undisclosed amount, indicating some inorganic platform activity. Operating geography is the United States, and the firm holds no disclosed institutional investors, parent company, or subsidiary structure.
ZZ Biotech firmographics
Firmographics- Name
- ZZ Biotech
- Legal name
- ZZ Biotech, LLC
- Website
- https://zzbiotech.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ZZ Biotech is a privately held, Houston-based clinical-stage biotech developing 3K3A-APC, an engineered variant of human activated protein C, and has licensed its dermatology program to Dermatherix for wound-therapy development.
- Ownership category
- akta.pro rank
ZZ Biotech industry classification
Industry- Product category
- Clinical Stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where ZZ Biotech is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ZZ Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Licensing Royalties: ZZ Biotech has been developing 3K3A-APC and has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. The company appears to be pre-revenue from product sales and is pursuing a licensing model for its drug development program.
ZZ Biotech product offering
Product offeringCore offering
ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company focuses on biologic treatments for ischemic stroke and has licensed its 3K3A-APC dermatology program to Dermatherix, Pty Ltd. for wound therapy applications. As a clinical stage biotech, ZZ Biotech monetizes its proprietary engineered protein IP through licensing arrangements rather than direct commercialization.
Product overview
ZZ Biotech is a biotech company that developed 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company has licensed its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd., while retaining its core development activities.
Differentiator
Problem solved
Functional benefit
Products and services
- 3K3A-APC 3K3A-APC is a genetically engineered variant of human activated protein C (APC), a serine protease, optimized for human therapeutic use and being developed for wound therapy and dermatology applications. It is intended for biotech and pharmaceutical partners seeking novel biologic assets for wound care and dermatology pipelines.
Companies that use ZZ Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
ZZ Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
ZZ Biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dermatherix, Pty Ltd.coreZZ Biotech has agreed in principle to license its 3K3A-APC program in dermatology to Dermatherix, Pty Ltd. Dermatherix is described as a pioneering biotech company dedicated to advancing wound therapies through innovative research. The 3K3A-APC program, which ZZ Biotech had been developing, will be advanced by the team at Dermatherix.
Recent moves4 records
Expansion highlights3 records
ZZ Biotech competitors and assessment
Company assessmentPeers
Direct peers
- ReNeuron Group: Clinical-stage company developing CTX stem cell therapy for stroke disability. Comparable to ZZ Biotech as a small clinical-stage biotech in the neuro-regeneration space with a single lead asset and limited headcount.
- SanBio: Clinical-stage regenerative medicine company developing SB623 cell therapy for chronic stroke and traumatic brain injury. Comparable to ZZ Biotech as a small clinical-stage biotech focused on CNS indications with a novel biologic and licensing/partnering strategy.
- Athersys: Clinical-stage biotech developing regenerative therapies for ischemic stroke (MultiStem cell therapy), with parallel programs in wound care/inflammatory conditions. Directly comparable to ZZ Biotech as a small-cap clinical-stage company targeting stroke with a novel biologic modality and seeking partnership-led commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
ZZ Biotech social profiles
Digital presenceZZ Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
ZZ Biotech leadership team
Management profileNumber of profiles
Profiles2 records
ZZ Biotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ZZ Biotech M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ZZ Biotech
What does ZZ Biotech do?
ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. The company focuses on biologic treatments for ischemic stroke and has licensed its 3K3A-APC dermatology program to Dermatherix, Pty Ltd. for wound therapy applications. As a clinical stage biotech, ZZ Biotech monetizes its proprietary engineered protein IP through licensing arrangements rather than direct commercialization.
Is ZZ Biotech a public or private company?
ZZ Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ZZ Biotech founded?
ZZ Biotech was founded in 2006. It employs 1 to 10 people.
Where is ZZ Biotech based?
ZZ Biotech is headquartered in Houston, United States, in the North America region.
How does ZZ Biotech make money?
One revenue line is on record: licensing Royalties.
Who are ZZ Biotech's main competitors?
BioAxone BioSciences is listed as a peer. Direct peers are ReNeuron Group, SanBio and Athersys.
Does ZZ Biotech have an API?
No public API is recorded for ZZ Biotech.
What industry is ZZ Biotech in?
ZZ Biotech's product category is Clinical Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.